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Background: Friedreich ataxia (FRDA) is a progressive inherited neurodegenerative disorder caused by mutation of
the FXN gene, resulting in decreased frataxin expression, mitochondrial dysfunction and oxidative stress. A recent
study has identified shorter telomeres in FRDA patient leukocytes as a possible disease biomarker.
Results: Here we aimed to investigate both telomere structure and function in FRDA cells. Our results confirmed
telomere shortening in FRDA patient leukocytes and identified similar telomere shortening in FRDA patient autopsy
cerebellar tissues. However, FRDA fibroblasts showed significantly longer telomeres at early passage, occurring in the
absence of telomerase activity, but with activation of an alternative lengthening of telomeres (ALT)-like mechanism. These
cells also showed accelerated telomere shortening as population doubling increases. Furthermore, telomere
dysfunction-induced foci (TIF) analysis revealed that FRDA fibroblasts have dysfunctional telomeres.
Conclusions: Our finding of dysfunctional telomeres in FRDA cells provides further insight into FRDA molecular disease
mechanisms, which may have implications for future FRDA therapy.
Keywords: Friedreich ataxia, FRDA, frataxin, FXN, GAA repeat expansion, Mouse model, Alternative lengthening of
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Friedreich ataxia (FRDA) is an autosomal recessive neuro-
degenerative disorder caused by GAA repeat expansion
mutation within intron 1 of the FXN gene. This leads to re-
duced frataxin expression, defective iron-sulphur cluster
(ISC) formation, mitochondrial iron accumulation and oxi-
dative stress, with eventual neuronal cell death. Previous
studies have reported FRDA fibroblasts to be more sensitive
to ionising radiation than control cells, suggesting that
FRDA may be a DNA damage response-deficient disorder
[1]. This is supported by gene expression studies of human
peripheral blood leukocytes that have indicated involve-
ment of DNA repair pathways in FRDA [2, 3]. It has also
been well documented that oxidative damage to DNA and
defects of DNA damage responses can cause accelerated
rates of telomere attrition and chromosomal instability [4].* Correspondence: mark.pook@brunel.ac.uk
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unless otherwise stated.Furthermore, a recent study of human peripheral blood
leukocytes has indicated telomere shortening in FRDA pa-
tients compared to healthy controls [5]. Therefore, we
aimed to further investigate telomere maintenance in
FRDA cells.
Telomeres play an essential role in the maintenance
of genomic stability via chromosome-end protection [6].
These specialised nucleoprotein structures form a loop to
protect the chromosome ends from exonuclease degrad-
ation and terminal fusions. Degradation of telomeres can
be caused by unresolved end-replication, exonuclease activ-
ity or DNA breakage within telomeric sequences due to
oxidative damage [4, 7, 8]. Telomere length maintenance is
carried out either by the activity of a telomere-specific
DNA polymerase called telomerase or by a telomerase-
independent pathway referred to as alternative lengthening
of telomeres (ALT) [6]. ALT cells are characterised by re-
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telomeres and promyelocytic leukemia protein (PML) nu-
clear bodies [9]. It is thought that ALT-associated PML
bodies (APBs) could provide templates for replication and
recombination-based telomere lengthening to enhance
telomere elongation or it may aid in recruitment of proteins
to the telomeric regions to facilitate inter-telomeric recom-
bination [10]. Normal human somatic cells do not have tel-
omerase or ALT activity, thus after a limited number of
divisions the cell population undergoes telomere-mediated
senescence due to short dysfunctional telomeres [11]. How-
ever, immortalised human cell lines either activate telomer-
ase or engage the ALT mechanism to maintain telomeres
through recombination. Therefore, the telomere length is
generally stable in these cells since equilibrium exists
between telomere degradation and telomere renewal [6].
Here, we have analysed the telomere length and rate of
telomere shortening in FRDA human and transgenic
mouse fibroblasts. We report that there is an initial com-
parative increase of telomere length in FRDA cells due to
ALT-like activation, followed by an increased rate of telo-
mere attrition due to telomere dysfunction, which may be
caused by a combination of oxidative stress and defective
DNA repair mechanisms. We also confirmed the previous
report of reduced telomere length in FRDA peripheral
blood leukocytes [5].Fig. 1 Telomere length analysis of FRDA cells. a Mean telomere length determ
increased telomeric repeat fluorescence in YG8R and YG22R FRDA mice c
also showed 6 times greater telomere fluorescence than the LY-S short telomer
Q-FISH showed significantly higher telomere fluorescence in all the FRDA fibrob
FRDA patient fibroblasts (n = 3) measured by qPCR was significantly grea
d Mean telomere length of the FRDA leukocytes (n= 18) measured by qPCR w
as mean ± SEM (*P < 0.05 and ***P < 0.001, evaluated by Student’s t test). All qP
independently, at least twiceResults
Telomere length analysis in human and mouse FRDA cells
and tissues
The telomere length in FRDA human and transgenic
mouse fibroblasts was measured by a Q-FISH protocol
adapted for interphase cells. A total of 100–150 interphase
nuclei per cell line were captured and the mean telomere
fluorescence intensity per cell was used to determine the
mean difference between FRDA fibroblasts and controls.
Initially, telomere fluorescence intensity was analysed in
mouse FRDA (YG8R and YG22R) and control (Y47R and
B6) fibroblasts at passage 7. To quantify the results, two
mouse lymphoma cell lines, LY-R and LY-S, with known
telomere lengths of 49 kb and 7 kb, respectively, were used
as calibration standards [12]. The results revealed that the
mouse FRDA cell lines, YG8R and YG22R, have signifi-
cantly increased telomeric repeat fluorescence (P < 0.001)
compared to the controls, Y47R and B6 (Fig. 1a). LY-R con-
trol cells were shown to have approximately 6 times greater
telomere fluorescence than LY-S control, which confirmed
the accuracy of the technique. Subsequently, telomere
fluorescence intensities of PNA probes were analysed in
human FRDA and control fibroblasts that had each under-
gone 7 passages subsequent to acquisition from the Coriell
Cell Repository (details are shown in Table 1). The results
showed that the mean telomere fluorescence intensity ofinations of mouse FRDA fibroblast cells by Q-FISH, showing significantly
ompared to Y47R and B6 controls. The LY-R long telomere control
e control. n= 100. b Mean telomere length of human FRDA fibroblasts by
last cells compared to the controls. n= 150. c Mean telomere length of the
ter than the normal fibroblast (n = 3) and epithelial controls (n = 3).
as significantly lower compared to the controls (n= 12). All data are shown
CR runs were performed in triplicate and each experiment was repeated
Table 1 Details of the human primary fibroblast cell lines
Samples Sex Age
(Year)
Race Number of
GAA repeats
Starting passage
number (Coriell)
GM08399 Female 19 N/A Normal 4
GM04503 Female 31 Caucasian Normal 12
GM07492 Male 17 Caucasian Normal 3
GM07545 Female 22 Caucasian Normal 5
GM03816 Female 36 Caucasian 330/380 5
GM04078 Male 30 Caucasian 541/420 2
GM03665 Female 13 Caucasian 445/740 7
Table 2 FRDA patient leukocyte DNA samples
Samplesa Sex Number of GAA repeats
CA Male 750/550
MH Male 1100/450
HK Male 750/630
LK Male 730/600
CR Male 930/570
RS Female 930/600
MS Female 700/700
JT Male 780/780
AB Female 950/300
AG Female 900/550
BL Male 1060/730
BQ Female 950/250
BT Male 930/760
IC Female 950/950
LH Female 800/250
MB Female 1000/250
RB Male 850/750
SK Female 900/650
aNB: Patient ages were not available
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fibroblast cells was significantly greater (P < 0.001) than
those of controls (Fig. 1b). The values for human FRDA
cells also appeared to be higher than those of the FRDA
mouse cells, suggesting potential differences due to factors
such as GAA repeat size. However, a direct comparison
between these human and mouse results cannot effectively
be made due to the relative rather than absolute nature of
the two experiments. To further confirm the Q-FISH re-
sults, qPCR was performed to evaluate the telomere length
in the human FRDA and control cell lines. Three epithelial
cell samples with known telomere length, previously mea-
sured by telomere repeat amplification (TRF), were used as
the controls to examine the accuracy of the technique. The
results obtained by qPCR were in good agreement with
those previously acquired by Q-FISH and TRF methods.
Overall, the results demonstrated that FRDA fibroblasts
have significantly higher average telomere length of 19 kb
compared to normal fibroblasts (14 kb, P < 0.001) and nor-
mal human breast epithelial cells (15 kb, P < 0.05) (Fig. 1c).
Subsequently, peripheral blood leukocyte genomic
DNA samples from 18 FRDA patients and 12 healthy
controls (details shown in Table 2) were used to measure
the telomere length by qPCR. The results indicated that,
although there was a considerable variation in the telo-
mere length of the patients (Additional file 1), the mean
telomere length was significantly (P < 0.05) shortened in
FRDA leukocyte cells compared to controls (Fig. 1d).
These results are in good agreement with those previ-
ously reported by Castaldo and colleagues [5]. Although
we were not able to investigate any correlation between
telomere length and age, as this data was not available to
us, we did investigate the correlations between telomere
length and gender or GAA repeat sizes, but no signifi-
cant correlations were observed (Additional file 2).
Next, we measured the telomere lengths of DNA samples
from cerebellum autopsy tissues from FRDA patients com-
pared with age-matched unaffected individuals to provide
in vivo validation of our observation made from fibroblast
cells in vitro. Human DNA sample details are shown in
Additional file 3. The results showed that telomere lengths
in FRDA cerebellar tissues were significantly reduced(P < 0.05) compared to those of unaffected age-matched
controls. However, there were no correlations between
telomere length and age of onset or GAA allele sizes
(Additional file 4).
Telomere elongation in FRDA fibroblasts is due to an
ALT-like mechanism and not telomerase activity
As FRDA fibroblasts were found to have chromosomes
with relatively longer telomeric repeats, it was hypothe-
sized that these cells might have overcome telomere
shortening through activation of telomerase. To investi-
gate this hypothesis, human FRDA fibroblast cells were
screened for expression of telomerase activity using the
telomeric repeat amplification protocol (TRAP) assay. In
this method, telomerase adds telomeric repeats to the
forward primer, provided that it is active in these cells.
The extended primer would then be amplified by qPCR
with a reverse primer complementary to the telomeric
repeat. The results revealed that telomerase activity was
not present in FRDA fibroblasts (Additional file 5). Con-
sequently, the FRDA cells were considered to be nega-
tive for telomerase activity. Since the TRAP assay is a
semi-quantitative method and there exists a strong cor-
relation between human telomerase reverse transcriptase
(hTERT) mRNA expression levels and telomerase activ-
ity [13], hTERT mRNA expression was measured in
FRDA cells. The quantitative assay for hTERT mRNA
expression was conducted using TaqMan qRT-PCR. The
results indicated that FRDA cells do not express the
Anjomani Virmouni et al. Molecular Neurodegeneration  (2015) 10:22 Page 4 of 11hTERT gene, further confirming lack of telomerase activ-
ity in these cells (Additional file 5). Since FRDA fibro-
blasts exhibited longer telomeres with no detectable
telomerase activity, we investigated another mechanism
of telomere length maintenance, commonly known as
ALT, by measuring ALT-associated PML bodies (APBs).
The enhanced formation of APBs in cells is an indicator
of ALT activity. FRDA cells were first examined for the
presence of PML bodies using immunofluorescence. No
difference was detected in the number and distribution
of PML nuclear foci in FRDA cells compared to controls.
Subsequently, co-localisation of PML bodies with telo-
meres was investigated in these cells using combined
immunofluorescence to PML followed by Q-FISH for
telomere detection (Fig. 2a,b). The results indicated thatFig. 2 ALT activation in FRDA fibroblasts. a Percentage of the PML bodies
cells, GM03665, GM03816 and GM04078, compared to GM07492 and HeLa
in U2OS ALT-positive control cells, n = 50. b Representation of APBs detect
ALT-positive control cells (+Ctrl) and HeLa ALT-negative control cells (−Ctrl). Inte
PNA probes (red). Nuclei were counterstained with DAPI. Scale bar = 10 μm. Wh
FRDA cells by CO-FISH showed a significant increase (P < 0.001) in T-S
d Representative CO-FISH results, showing T-SCEs events (indicated b
ALT-positive controls (+Ctrl) and HeLa ALT-negative controls (−Ctrl). G
Student’s t test). All the experiments were repeated independently, ain 50 randomly analysed FRDA cells, approximately
35 % of the PML foci co-localised with telomeric DNA.
By comparison, the mean co-localisation values of PML
and telomeres in ALT positive U2OS cells, normal hu-
man fibroblasts and HeLa negative controls were 99 %,
11 % and 8 % respectively (Fig. 2a,b). These results sug-
gested that an ALT-like mechanism is involved in FRDA
cells but it is not as prominent as in ALT positive cells.
Previous results have shown that cellular stress may pro-
mote aggregation of PML bodies or conversely disperse
them into microspeckles [14]. Therefore, the size of co-
localised PML bodies with telomeres was examined.
However, no significant difference was detected in the
size of telomere-associated PML bodies compared with
non-telomere-associated PML bodies in FRDA cellsassociated with telomeres demonstrate high co-localisation in all FRDA
controls. 99 % of the telomere foci co-localised with the PML bodies
ed by immuno-FISH in FRDA and control (normal) fibroblast cells, U2OS
rphase cells were stained with anti-PML (green) and telomeric Cy3-labeled
ite arrowhead indicates an APB in a FRDA cell. c T-SCE analysis of human
CE levels of FRDA cells compared to the controls, n = 20–50.
y arrowheads) in FRDA and control (normal) fibroblasts, U2OS
raph data are shown as mean ± SEM (***P < 0.001, evaluated by
t least twice
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provide any further information regarding the assembly
or disassembly of PML bodies in FRDA cells due to cel-
lular stress. Subsequently, telomere recombination fre-
quencies between sister telomeres were analysed in
human FRDA and control primary fibroblasts, using the
chromosome orientation FISH (CO-FISH) method. This
method is used to measure levels of T-SCE – another
marker of ALT activity in cells. The results indicated a
significant increase (P < 0.001) in T-SCE levels in FRDA
cells compared to controls (Fig. 2c,d). These results sug-
gested that T-SCEs occur much more frequently in
FRDA cells than normal cells, further confirming the ex-
istence of an ALT-like mechanism in these cells.
Accelerated telomere shortening in FRDA fibroblasts
To investigate whether FRDA fibroblasts can activate an
ALT-like mechanism during culturing in vitro to become
immortalised, growth curves and cumulative population
doubling time analyses were performed. Growth curve ana-
lysis of human FRDA and control fibroblasts was carried
out from the earliest passage number available for each cell
line. FRDA fibroblasts underwent growth arrest after 124 to
175 days with average cumulative population doubling of
47. In contrast, normal fibroblasts exhibited earlier growthFig. 3 Increase of time to senescence and accelerated telomere shortening
human FRDA and normal fibroblast cell lines. Every cell passage is indicate
proliferations over the cumulative time taken from the earliest passages until ce
the human FRDA and normal fibroblasts in bp/population doubling. P7, P15 an
Cell Repository (Table 1), respectively. Data are shown as mean ± SEM. Al
c The telomere length shortening (bp/PD) of FRDA fibroblasts comparedarrest, after 124 to 138 days, with an average of 36 cumula-
tive population doubling (Fig. 3a). These results indicated
that FRDA cells were not immortalised by the ALT-like
mechanism alone, suggesting that the frequency of the
PML bodies may not have been sufficient to prevent senes-
cence. However, FRDA cells senesced on average approxi-
mately 11 population doublings later than the controls
(P < 0.001). The presence of senescent cells was confirmed
by β-galactosidase (β-Gal) assay (Additional file 7). This
delay in transition from proliferation to senescence in
FRDA cells could in part be due to the difference in the
original telomere lengths of these cell lines. Subsequently,
the effect of replicative aging of culture cells at the 7th,
15th and 26th passages following acquisition from the
Coriell Cell Repository (Table 1) was studied by qPCR
telomere length assay to determine telomeric DNA loss
due to cell divisions. The results of this analysis revealed
an accelerated telomere shortening in FRDA fibroblasts,
taking initial differences in passage numbers into consider-
ation (Fig. 3b). Although initial results indicated that
FRDA fibroblasts contained relatively longer telomeres
compared to controls after 7 passages, further analysis
after 15 and 26 passages showed that these cells reduced
telomere length more rapidly throughout culture than
normal cells (Fig. 3b). FRDA fibroblasts showed an averageof FRDA fibroblasts. a Cumulative population doubling (CPD) times of
d by a point and the CPD was calculated based on the sum of the cell
lls underwent senescence. b The average rates of telomere shortening in
d P26 = 7th, 15th and 26th passages following acquisition from the Coriell
l the experiments were repeated at least twice independently, n = 3.
to controls throughout growth
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which was four times greater than the 47 bp average value
of normal fibroblasts (Fig. 3c). The accelerated telomere
shortening observed in FRDA fibroblasts suggested that
the telomeres may be dysfunctional in these cells.
Investigation of telomere dysfunction in FRDA fibroblasts
To confirm the presence of a telomere dysfunction pheno-
type in FRDA fibroblasts, the telomere dysfunction-induced
foci (TIF) assay was performed using an antibody against
DNA damage marker γ-H2AX together with the synthetic
PNA telomere probe. The presence of TIFs in a cell is indi-
cative of DNA damage at telomeres [15] and is used to
quantitatively measure levels of telomeric dysfunction. As
evident in Figs. 4 a and c, the frequency of γ-H2AX foci
was significantly higher in FRDA cells compared to controlsFig. 4 Frequencies of γ-H2AX positive foci and TIFs in FRDA fibroblast cells. a A
GM03816, GM04078), unaffected fibroblasts (GM07492, GM04503), U2OS A
(−Ctrl), n = 50–100. b Average TIFs in each corresponding cell line, n = 50–100
Student’s t test). c Representative images showing detection of γ-H2AX b
ALT-positive control cells (+Ctrl) and HeLa ALT-negative control cells (−C
(green) and telomeric Cy3-labeled PNA probes (red). Nuclei were counterstain
(yellow). Scale bar = 10 μm. All experiments were repeated independently, at(P < 0.001). Similarly, FRDA cells had greater TIF frequen-
cies in comparison to controls (P < 0.001) (Fig. 4b,c), indi-
cating that FRDA fibroblasts have greater induced telomere
dysfunction.
Discussion
FRDA cells are known to exhibit increased susceptibility
to oxidative stress, an important modulator of telomere
length [4, 16]. Therefore, we hypothesised that telomeres
might be shortened in FRDA patient cells. However, our
initial results showed that both human and mouse FRDA
fibroblasts appear to have significantly longer, rather
than shorter, telomere lengths compared to normal con-
trol fibroblasts, with the caveats that there is variability
within these systems and our results are based on the
analysis of only three human and two mouse FRDA cellverage number of γ-H2AX positive foci in FRDA fibroblasts (GM03665,
LT-positive control cells (+Ctrl) and HeLa ALT-negative control cells
. Data are shown as mean ± SEM (**P < 0.01 and ***P < 0.001, evaluated by
y immuno-FISH in FRDA and control (normal) fibroblast cells, U2OS
trl). Interphase cells were stained with antiphospho-histone γ-H2AX
ed with DAPI (blue). White arrowheads in merged images indicate TIFs
least twice
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This contrasts with the results of a recent study by
Castaldo and colleagues that showed significant telomere
shortening in human FRDA leukocytes [5]. Therefore,
we further examined telomere length in our own collec-
tion of FRDA leukocyte genomic DNA samples to inves-
tigate this apparent discrepancy. However, we identified
a significantly shortened mean telomere length in FRDA
leukocytes compared with controls, which is in good
agreement with the previous study by Castaldo and col-
leagues [5]. In addition, we showed that the telomere
lengths from FRDA cerebellum autopsy tissues were sig-
nificantly shorter than those of unaffected age-matched
controls. However, we identified considerable variation
in the telomere lengths of different FRDA patient
leukocyte and cerebellum tissue samples and there were
no correlations between telomere lengths and age of on-
set or GAA repeat size, which casts some doubt upon
the potential use of telomere length as an effective bio-
marker of FRDA disease severity. However, telomere
length may still be a useful biomarker of FRDA disease
progression, as proposed by Castaldo and colleagues [5].
By analyzing fibroblasts, leukocytes and cerebellar tis-
sues, we have shown that there is variation of telomere
length within different FRDA cell and tissue types. This
may be due to several factors, including differences in
cellular replication status and different cellular environ-
ments, as the replicating fibroblasts were grown in vitro,
while the primarily non-replicating leukocytes and cere-
bellar tissues were obtained in vivo.
We further showed that FRDA fibroblasts do not
maintain telomeres due to telomerase activity, but rather
due to activation of an ALT-like mechanism. The causes
of ALT activation are not fully understood. However,
mutations in the ATRX/DAXX chromatin remodelling
complex and histone H3.3 have been found to correlate
with ALT [17]. Also, it has been observed that mismatch
repair (MMR) defects can facilitate ALT engagement in
yeast [18]. It has also been shown that FRDA cells are
more sensitive to ionising radiation than the control
cells [1]. Furthermore, gene expression analysis of FRDA
patient blood samples has identified reduced expression
of DNA repair genes [2, 3], suggesting that FRDA may
be a DNA repair-deficient disorder. This notion is sup-
ported by our current findings of high frequencies of
γ-H2AX and TIFs in FRDA fibroblasts compared to
the controls, indicating a higher degree of DNA dam-
age in FRDA cells. Therefore, an ALT-like mechanism
may become activated in FRDA cells due to a combin-
ation of oxidative DNA damage and defective DNA re-
pair mechanisms. However, we also showed that
FRDA fibroblasts were unable to become immortalised
during long-term growth in culture, indicating that
the ALT-like activity was not sufficient to overcomecellular senescence. The reason why we did not ob-
serve a complete engagement of the ALT-like pathway
in FRDA telomere maintenance may be due to defect-
ive DNA repair systems or alteration of the hetero-
chromatic state of telomeres [9]. Nevertheless, FRDA
cells were found to senesce approximately 11 popula-
tion doublings later than the controls. This extension
of the transition time from proliferation to senescence
could be partly due to the difference in the original
telomere lengths of these cell lines, in addition to the
selective activation of the ALT-like mechanism. We
also identified a faster telomere attrition rate in FRDA
cells compared with controls, suggesting telomere dys-
function, which again could be due to oxidative DNA
damage and defective DNA repair mechanisms [4] or
due to an altered heterochromatic state of the telomeres,
resulting in the repression of telomeric recombination [9].
Accelerated loss of telomere lengths has also been reported
in other neurodegenerative diseases that are associated with
oxidative stress, such as Alzheimer’s disease and Parkinson’s
disease, suggesting the existence of common molecular dis-
ease mechanisms [19, 20]. However, it is possible that the
accelerated telomere shortening that we identified in FRDA
fibroblast cells could be an artefact of in vitro culture and
in fact in vivo skin cells from FRDA patients have a normal
rate of telomere shortening. Therefore, the exact mecha-
nisms of telomere shortening under conditions of oxidative
stress require further investigation, for example by repeated
skin biopsy sampling throughout age from individual FRDA
patients or repeated tissue sampling FRDA mouse models.
Dysfunctional telomeres in FRDA cells may occur due to
defects in a variety of potential genes or proteins that are
essential for DNA repair and telomere maintenance, in-
cluding DNA-PKcs, Ku70/80, TRF2, ATM, PARP, BRCA1,
BRCA2 and DNA helicases [21–29]. These may also in-
clude enzymes that require iron sulfur cluster (ISC) cofac-
tors for activity. For example, recent findings indicate that
RTEL1, the ISC-containing DNA helicase regulator of telo-
mere length 1, is essential for telomere homeostasis by cata-
lysing T-loop disassembly during S phase and therefore its
deficiency is associated with removal of the T loop struc-
tures and rapid telomere shortening [30, 31]. In addition,
methyl methanesulfonate sensitive 19 (MMS19), a yeast
member of the cytosolic ISC assembly (CIA) machinery,
has been found to function as the most interactive partner
of RTEL1 [32]. Therefore, the reported sensitivity of
MMS19 deficient cells to DNA damage and the presence of
extended telomeres may be attributed to the function of
MMS19 in telomere maintenance.
Other studies have also found a link between epigen-
etic status of subtelomeres and telomere length regula-
tion, suggesting a role for subtelomeric methylation in
telomere-length homeostasis [33, 34]. Telomeres have a
closed conformation, mediated by the interaction of
Anjomani Virmouni et al. Molecular Neurodegeneration  (2015) 10:22 Page 8 of 11DNA with epigenetic markers. As telomeres become
shorter, the heterochromatic markers are decreased from
telomeres and subtelomeres, which lead to a less dense
conformation, allowing a greater accessibility for telo-
mere elongating activities [35]. An increase in the hyper-
methylation of the shortest telomeres has been reported
in patients with Alzheimer’s disease [36], whereas, hypo-
methylated subtelomeres have been reported to be asso-
ciated with increased telomeric shortening in patients
with Parkinson’s disease [37]. It has also been shown
that short telomeres with hypomethylated subtelomeres
tend to be lost faster than those with enhanced subtelo-
meric methylation [37–40]. These results suggested that
oxidative stress in neurodegenerative disorders might
affect the access of the DNA methyltransferase to subte-
lomeres, thus resulting in subtelomeric hypomethylation
and consequential progress to cell death [41]. To date,
none of these telomere length-associated changes have
been investigated in FRDA patients. Therefore, further
analysis is required to clarify the correlation between
telomere length and methylation status in FRDA cells.
Conclusions
Overall, the results presented in this study demonstrate a
telomere dysfunction phenotype and accelerated telomere
shortening in FRDA fibroblasts, together with compara-
tively reduced telomere lengths in both FRDA leukocytes
and cerebellar tissues. In addition, we observed that ALT-
like inter-telomeric recombination was initiated in FRDA fi-
broblasts, but this was incapable of preventing accelerated
telomere shortening. Our studies support an FRDA mo-
lecular disease model whereby oxidative DNA damage, in
combination with defective DNA repair responses and per-
haps epigenetic changes, induce suboptimal ALT-like telo-
meric recombination. However, it remains unclear why
there is not a prolonged effect of the ALT-like mechanism
on FRDA telomere length and this requires further analysis.
Cell type-specific factors are likely to contribute to the telo-
mere length maintenance, hence further experiments using
different cell types will further enhance our understanding
of the correlation between telomere length in FRDA with
various genetic and cellular risk factors. Furthermore, our
observations may have an impact on future FRDA thera-
peutic strategies. Since telomere shortening plays an im-
portant role in human cell viability, telomere length
may yet prove to be a useful biomarker of cumulative
exposure to oxidative stress and defective DNA re-
sponses in FRDA disease progression and subsequent
amelioration by therapy.
Methods
Cell culture
Mouse fibroblast cell lines were established from the kidney
tissues of C57BL/6 J (B6) mice and previously reportedFXN YAC transgenic mouse models: Y47R (9 GAA
repeats), YG8R (90 and 190 GAA repeats) and YG22R
(190 GAA repeats) [42, 43]. All human fibroblasts derived
from FRDA patients and unaffected controls were ob-
tained from the Coriell Cell Repository (Table 1). Cells
were cultured in DMEM culture medium (Gibco) supple-
mented with 10-15 % fetal bovine serum (Gibco) and 2 %
penicillin-streptomycin (Gibco) at 37 °C with 5 % CO2.
Mouse lymphoma LY-R (radio-resistant) and LY-S (radio-
sensitive) cells were cultured in RPMI 1640 medium (Invi-
trogen) supplemented with 10 % FBS and 2 % Pen-Strep
at 37 °C with 5 % CO2. U2OS (human osteosarcoma) and
HeLa (human cervical carcinoma) cell lines were pur-
chased from ECCC (European Collection of Cell Culture)
and ATCC (American Tissue Culture Collection), respect-
ively. The U2OS cell line was grown in McCoy’s culture
medium (Sigma-Aldrich) supplemented with 10 % FBS,
2 % Pen-Strep and 2 mM glutamine (Gibco) at 37 °C with
10 % CO2. The HeLa cell line was grown in DMEM cul-
ture medium supplemented with 10 % FBS and 2 % Pen-
Strep at 37 °C with 10 % CO2. For growth curve analysis,
FRDA and control fibroblast cell lines were serially pas-
saged by re-seeding at 100,000 cells/25 cm2 flasks (Fisher
Scientific) and harvesting at 80 % confluence from earliest
passage until they entered replicative senescence. For each
harvest, cells were counted with a haemocytometer (Invi-
trogen) and transferred every 6–7 days. Cell population
doublings per passage (PDP) and cumulative population
doublings (CPD) were calculated from the first passage on-
ward by the following formula [44]: PD = (Log N1 /Log2)-
(Log No / Log2); CPDn =ΣPD(1, n), where No is the number
of cells at the beginning; N1 is the number of cells at
the end of each cell culture period and n is the number
of passages. β-galactosidase activity was determined as
described [45].DNA extraction and telomere length measurement
Genomic DNA was extracted from FRDA and control
human and mouse fibroblasts, blood samples and cere-
bellum autopsy tissues by standard phenol/chloroform
extraction and ethanol precipitation. Telomere length
was determined by a previously described quantitative
polymerase chain reaction (qPCR) method [46]. In brief,
the relative telomere length was calculated from the ra-
tio of the telomere (T) repeat copy number to a single
gene (36B4, which encodes the acid ribosomal phospho-
protein PO) (S) copy number (T/S ratio) for each sample
using standard curves. For quality control, all qPCR telo-
mere length measurements were performed in triplicate.
To quantify telomere shortening per PD, the following
formula was used: (N1-No) / CPD, where No is the telo-
mere length at the initial passage and N1 is the telomere
length at the later passage.
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Interphase quantitative fluorescent in situ hybridisation
(IQ-FISH) was performed using the FITC-conjugated
peptide nucleic acid (PNA) telomeric oligonucleotide
(CCCTAA)3 probe as previously described [47]. Images
of interphase cells were acquired on a digital fluores-
cence microscope (Zeiss Axioskop 2) equipped with a
CCD camera (Photometrics) and Smart Capture soft-
ware (Digital Scientific) using fixed exposure time of
0.5 second and magnification of 63×. Telomere fluores-
cence intensity per cell was analysed using IP Lab soft-
ware (Digital Scientific) and the average signal was
evaluated by subtracting the background signal from the
total telomeric signal intensity.
Chromosome orientation fluorescence in situ hybridisa-
tion (CO-FISH) was performed as previously described
[48]. Briefly, cells were grown in the presence of BrdU/
BrdC (3:1) (Sigma Aldrich) at a concentration of 1 × 10−5
for 24 h. Slides containing chromosome preparation were
stained with DNA-binding fluorescent dye Hoechst 33258
(0.5 μg/ml; Sigma Aldrich) for 15 min at room temperature
and were exposed to 365 nm UV light (Stratelinker 1800
UV irradiator) for 30 min. The nicked BrdU-substituted
DNA strands were then digested by 3U/ml of Exonuclease
III (Promega) in the buffer supplied by the manufacturer at
room temperature for 10 min. In situ hybridisation was per-
formed using the Cy3-conjugated PNA telomeric oligo-
nucleotide (CCCTAA)3 probe as previously reported [49].
Images of metaphase spreads were acquired using a Zeiss
fluorescence microscope equipped with a CCD camera
(Photometrics) and ISIS Capture software (in situ imaging
system “ISIS”, Meta Systems, Altlussheim, Germany).
Telomere dysfunction induced foci (TIF) assays were
performed as previously described [50]. Briefly, cells
were grown on poly-L-lysine-coated slides (Poly-Prep
slides, Sigma-Aldrich) for 24 h prior to immunofluores-
cence staining. The slides were fixed in 4 % formalde-
hyde in PBS for 15 min and were permeabilised with
0.2 % Triton X-100 (Sigma-Aldrich) for 10 min at 4 °C.
The cells were then blocked with 0.5 % BSA in PBS for
30 min. 100 μl of mouse monoclonal antiphospho-
histone H2AX (Ser 139, Millipore) was added to the
slides at the desired concentration (1:500 in 0.5 % BSA/
PBS) and the slides were incubated for 1 h in a humid
container. After three washes in TBST (Tris-Buffered
Saline with 0.1 % Tween20) for 5 min, the slides were
incubated with 100 μl of secondary FITC-conjugated
anti-mouse IgG antibody (Sigma) at the desired con-
centration (1:1000 in 0.5 % BSA/PBS) for 1 h in a
humid container. The slides were washed again as
above and hybridised for 2 min at 70-75 °C with Cy3-
conjugated PNA (CCCTAA)3 probe. The slides were
analysed using a Zeiss fluorescence Axioplan micro-
scope equipped with a CCD camera and Smart Capturesoftware. The frequency of γH2AX was analysed from
the TIF results since the TIF protocol simultaneously
detects γH2AX foci and telomeres.
For immuno-FISH, cells were grown on poly-L-lysine-
coated slides (Poly-Prep slides, Sigma-Aldrich) for 24 h,
then fixed in ice-cold methanol-acetone (1:1) for 10 min
and washed three times in PBS. The cells were then
blocked with 1 % NCS (Newborn Calf serum) in PBS for
30 min. 75 μl of promyelocytic leukemia (PML) primary
antibody (Rabbit polyclonal antibody against PML,
ab53773, Abcam) was added to the slides at the desired
concentration (1:100 in 1 % NCS/PBS) and the slides were
then incubated for 1 h in a humid container. The slides
were then washed three times in PBS for 5 min. 75 μl
of anti-rabbit secondary antibody labelled with FITC
(F1262-1ML, Sigma) was added to the slides at the de-
sired concentration (1:100 in 1 % NCS/PBS) and the
slides were subsequently incubated for 1 h in a humid
container. After rinsing in PBS, the FISH method was
applied with a Cy3-conjugated PNA probe (CCCTAA)3
followed by standard formamide and SSC washes. Cells
were counterstained with DAPI and were examined on
a Zeiss Axioplan fluorescence microscope equipped
with a CCD camera (Photometrics) and Smart Capture
software (Digital Scientific) using fixed exposure time
of 1 s and magnification of 1000×. The co-localisation
of PML and telomere signals was analysed using ImageJ
software (National Institutes of Health, Bethesda, MD).
Telomerase assay
Cells (105-106) were lysed in 200 μl of CHAPS buffer, con-
taining RNase inhibitor, and were incubated at 4 °C for
30 min. The lysates were then centrifuged at 15700 X g for
20 min at 4 °C. The protein concentration was measured
using a Pierce® BCA Protein Assay Kit (Thermo scientific)
following the manufacturer’s instructions. In order to ob-
tain the final concentration of 125 ng/μl, the protein con-
centration of the tested samples was measured from the
standard curve and the samples were diluted in CHAPS
lysis buffer accordingly. Telomerase activity was measured
using TRAPEZE® Telomerase Detection Kit (Chemicon,
Millipore) according to the manufacturer’s instructions.
Gene expression of hTERT using qRT-PCR
Total RNA was extracted from 106 cells using the Trizol®
method (Invitrogen) and reverse transcribed using AMV
reverse transcriptase (Invitrogen) with random hexanucleo-
tide primers following the manufacturer’s instructions.
hTERT mRNA expression levels were quantified by
qRT-PCR using an ABI Prism 7900HT Sequence Detec-
tion System and TaqMan® Fast Universal Master Mix
(Applied Biosystems) [51]. An hTERT assay (Applied
Biosystems), containing hTERT forward (5′-GAGCTG
ACGTGGAAGATGAGC-3′) and reverse (5′-GGTG
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TaqMan TAMRA™ probe (5′-CACGGTGATCTCTGC
CTCTGCTCTCC-3′) giving a 260 bp fragment, and a
GAPDH assay (Assay ID: Hs99999905_m1, 124 bp
amplicon size, Applied Biosystems), containing GAPDH
forward and reverse primers and a TaqMan MGB probe,
were used in this experiment. The cycling protocol con-
sisted of 20 s at 95 °C, followed by 50 cycles (95 °C for 1 s
and 60 °C for 20 s). Reactions were carried out in triplicate
for each sample.
Statistical analysis
Comparisons between population doublings were assessed
by two-way analysis of variance (ANOVA) while relation-
ships between telomere length and other variables were cal-
culated by multiple regression analysis. All other data were
analysed by the Student’s t test, with a significance value set
at P < 0.05.
Additional files
Additional file 1: Figure S1. Variation in telomere length of human
leukocytes. Telomere length measurements using qPCR showed that
there was a variation in the telomere length of the FRDA patients and
control leukocytes. Data are shown as mean ± SEM. QPCR runs were
performed in triplicate and repeated twice from independent samples.
Additional file 2: Figure S2. Effect of gender and size of GAA repeats
on telomere length in FRDA leukocytes. (A) Mean telomere length
values ± SEM of FRDA male and female leukocytes (P = 0.4, evaluated
by Student’s t test). (B and C) Linear regression analysis was used to
assess the correlation between telomere length and size of the smaller
(B) or larger GAA repeats (C) in FRDA leukocytes.
Additional file 3: Table 1. FRDA and control DNA samples from
human cerebellum tissues.
Additional file 4: Figure S4. Telomere length analysis in FRDA cerebellum
tissues. (A) Box-plot display of telomere length distributions in the cerebellum
tissues of FRDA patients and age-matched controls (*P< 0.05, evaluated by
Student’s t test). QPCR runs were repeated twice from independent
samples. (B, C and D) Linear regression analysis was used to assess
the correlation between telomere length and age of onset (B), size of
the larger (C) or smaller GAA repeats (D) in FRDA cerebellum tissues,
n =10-13.
Additional file 5: Figure S5. Telomerase activity in FRDA fibroblasts.
(A) Telomerase activity determined by the TRAP assay in FRDA cells. The
breast cancer cell line 21NT was used as the positive control. No
template control (NTC) and minus telomerase control (MTC) served as
the negative controls. Data are shown as mean ± SEM. The experiment
was repeated twice from independent samples. (B) Products of hTERT
transcripts in FRDA fibroblast cells. The breast cancer cell lines 21NT and
21MT were used as the positive controls. Normal human fibroblast
GM07492 and GM08399 cell lines, normal breast epithelial cell line and
NTC (No Template Control) served as the negative controls.
Additional file 6: Figure S6. Size analysis of associated and non-
associated PML bodies with telomeres. The sizes of the PML bodies
(associated and non-associated) were analysed in FRDA cell lines
(P = 0.44) and positive control U2OS (P = 0.99, evaluated by Student’s
t test) using ImageJ software. Data are shown as mean ± SEM, n= 50–150.
Additional file 7: Figure S7. β-galactosidase detection in FRDA
Fibroblasts. Early and late passaged FRDA fibroblast cells were assayed
for β-galactosidase activity. Growing 293 T cells and senescing human
mammary epithelial cells (HMECs) were used as negative (−ve) and
positive (+ve) controls respectively, scale bar = 100 μm.Abbreviations
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